Cargando…

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine

Indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) inhibits T-cell activation and promotes T-cell differentiation into regulatory T-cells. Moreover, IDO expression promotes resistance to immunotherapies targeting immune checkpoints such as the cytotoxic T lymphocyte antigen-4 (CTL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sioud, Mouldy, Nyakas, Marta, Sæbøe-Larssen, Stein, Mobergslien, Anne, Aamdal, Steinar, Kvalheim, Gunnar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967686/ https://www.ncbi.nlm.nih.gov/pubmed/27504122 http://dx.doi.org/10.1155/2016/9639585

Ejemplares similares

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
por: Jarnjak-Jankovic, Silvija, et al.
Publicado: (2007)

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
por: Vik-Mo, Einar Osland, et al.
Publicado: (2013)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
por: Mobergslien, Anne, et al.
Publicado: (2016)

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
por: Sioud, Mouldy, et al.
Publicado: (2015)

The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma
por: Jia, Huijie, et al.
Publicado: (2018)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
por: Aamdal, E., et al.
Publicado: (2022)

Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia
por: Jarnjak-Jankovic, Silvija, et al.
Publicado: (2005)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
por: Maggadóttir, Sólrún Melkorka, et al.
Publicado: (2022)

Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues
por: Sæbøe-Larssen, Stein, et al.
Publicado: (2006)

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
por: Suso, Else M. Inderberg, et al.
Publicado: (2011)

Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
por: Sioud, Mouldy
Publicado: (2019)

Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
por: Sioud, Mouldy
Publicado: (2021)

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
por: Ge, Shushan, et al.
Publicado: (2020)

RNA Interference
por: Sioud, Mouldy, et al.
Publicado: (2006)

Molecular Basis for the Immunostimulatory Potency of Small Interfering RNAs
por: Sioud, Mouldy, et al.
Publicado: (2006)

Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting
por: Zhang, Qindong, et al.
Publicado: (2023)

Precision Killing of M2 Macrophages with Phage-Displayed Peptide-Photosensitizer Conjugates
por: Sioud, Mouldy, et al.
Publicado: (2023)

Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells
por: Sioud, Mouldy, et al.
Publicado: (2023)

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
por: Hamid, Omid, et al.
Publicado: (2011)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Evidence for the involvement of G(i2) in activation of extracellular signal-regulated kinases in hepatocytes
por: Melien, Øyvind, et al.
Publicado: (2001)

Structural Requirements for the Binding of a Peptide to Prohibitins on the Cell Surface of Monocytes/Macrophages
por: Zhang, Qindong, et al.
Publicado: (2022)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
por: Sioud, Mouldy, et al.
Publicado: (2019)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Blockade of MIF–CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma
por: Figueiredo, Carlos R., et al.
Publicado: (2018)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
por: Mu, L J, et al.
Publicado: (2005)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_golo1ako4afg4hotee93frl7rn